Jonathan A. Bernstein
Experienced in RASopathies

Dr. Jonathan A. Bernstein

Medical Genetics | Pediatrics
725 Welch Rd, 
Palo Alto, CA 
Experienced in RASopathies
725 Welch Rd, 
Palo Alto, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jonathan Bernstein is a Medical Genetics specialist and a Pediatrics provider in Palo Alto, California. Dr. Bernstein is rated as an Experienced provider by MediFind in the treatment of RASopathies. His top areas of expertise are Hereditary Angioedema, Chronic Spontaneous Urticaria (CSU), Hypotonia, and Smith-Kingsmore Syndrome.

His clinical research consists of co-authoring 661 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of RASopathies.

Specialties
Medical Genetics
Pediatrics
Licenses
Medical Biochemical Genetics in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

725 Welch Rd, Palo Alto, CA 94304
Other Locations
300 Pasteur Dr, SUMC - Peds Physician Billing Services, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1/2 Open-Label, Dose-Escalation Study to Determine the Safety Tolerability & Efficacy of BMN 331 an AAV Vector-Mediated Gene Transfer of Human SERPING1 Gene in Subjects With HAE Due to Human C1-INH Deficiency
A Phase 1/2 Open-Label, Dose-Escalation Study to Determine the Safety Tolerability & Efficacy of BMN 331 an AAV Vector-Mediated Gene Transfer of Human SERPING1 Gene in Subjects With HAE Due to Human C1-INH Deficiency
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2024
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
An Open-Label, Pilot Study to Assess the Efficacy and Safety of AK002 (Siglec-8) in Subjects With Antihistamine-Resistant Chronic Urticaria
An Open-Label, Pilot Study to Assess the Efficacy and Safety of AK002 (Siglec-8) in Subjects With Antihistamine-Resistant Chronic Urticaria
Enrollment Status: Completed
Publish Date: March 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: No_longer_available
Publish Date: July 24, 2023
Intervention Type: Drug
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: CDX-0159, Normal Saline
Study Phase: Phase 1
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
Enrollment Status: Completed
Publish Date: March 30, 2023
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: Dupilumab
Study Phase: Phase 4
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
Enrollment Status: Completed
Publish Date: November 03, 2020
Intervention Type: Device
Study Phase: Not Applicable
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody
Enrollment Status: Completed
Publish Date: July 10, 2019
Intervention Type: Biological
Study Phase: Phase 4
View 9 Less Clinical Trials
Similar Doctors
Distinguished in RASopathies
Dr. Ophir D. Klein
Medical Genetics | Pediatrics
Distinguished in RASopathies
Dr. Ophir D. Klein
Medical Genetics | Pediatrics
513 Parnassus Ave, Room S747, Box 0442, 
San Francisco, CA 
 (27.4 miles away)
415-476-2221
Languages Spoken:
English
See accepted insurances

Ophir Klein is a Medical Genetics specialist and a Pediatrics provider in San Francisco, California. Dr. Klein is rated as a Distinguished provider by MediFind in the treatment of RASopathies. His top areas of expertise are Costello Syndrome, RASopathies, Ectodermal Dysplasias, and Clouston Syndrome.

Advanced in RASopathies
Dr. David Stevenson
Medical Genetics | Pediatrics
Advanced in RASopathies
Dr. David Stevenson
Medical Genetics | Pediatrics

Lpch Medical Group Div Of Lucile

725 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
650-498-7200
Languages Spoken:
English
See accepted insurances

David Stevenson is a Medical Genetics specialist and a Pediatrics provider in Palo Alto, California. Dr. Stevenson is rated as an Advanced provider by MediFind in the treatment of RASopathies. His top areas of expertise are Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Cardiomyopathic Lentiginosis, and Cardiofaciocutaneous Syndrome.

Advanced in RASopathies
Dr. Ana Melikishvili
Pediatrics | Neurology | Pediatric Neurology
Advanced in RASopathies
Dr. Ana Melikishvili
Pediatrics | Neurology | Pediatric Neurology
5820 Owens Dr, 
Pleasanton, CA 
 (30.1 miles away)
Experience:
18+ years
Languages Spoken:
English
See accepted insurances

Ana Melikishvili is a Pediatrics specialist and a Neurologist in Pleasanton, California. Dr. Melikishvili has been practicing medicine for over 18 years and is rated as an Advanced provider by MediFind in the treatment of RASopathies. Her top areas of expertise are Legius Syndrome, Generalized Tonic-Clonic Seizure, Seizures, and RASopathies.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bernstein's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile